A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Recruitment Status
ACTIVE, NOT RECRUITING
(See Contacts and Locations)Verified August 2025 by Merck Sharp & Dohme LLC
Sponsor
Merck Sharp & Dohme LLC
Information Provided by (Responsible Party)
Merck Sharp & Dohme LLC
Clinicaltrials.gov Identifier
NCT05933577
Other Study ID Numbers:
V940-001
First Submitted
June 26, 2023
First Posted
July 5, 2023
Last Update Posted
September 23, 2025
Last Verified
August 2025

ClinicalTrials.gov processed this data on September 2025. Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

Condition or DiseaseIntervention/Treatment
Melanoma
Biological: Intismeran autogeneBiological: Pembrolizumab

Study Design

Study TypeInterventional
Actual Enrollment1089 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingTriple
Primary PurposeTreatment
Official TitleA Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)
Study Start DateJuly 18, 2023
Actual Primary Completion Date3yrs 1mo from now
Actual Study Completion Date4yrs 4w from now

Groups and Cohorts

Group/CohortIntervention/Treatment
Intismeran autogene + Pembrolizumab
Participants receive up to 9 doses of intismeran autogene via an intramuscular (IM) injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an intravenous (IV) infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner.
Biological: Intismeran autogene
IM injection
Placebo + Pembrolizumab
Participants receive up to 9 doses of dose matched placebo to intismeran autogene via an IM injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an IV infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner.
Biological: Pembrolizumab
IV infusion

Outcome Measures

Primary Outcome Measures
  1. Recurrence-Free Survival (RFS)
    RFS is defined as the length of time from when the participant starts the study until either the cancer comes back, or the cancer spreads as assessed by the investigator, or death due to any cause.
Secondary Outcome Measures
  1. Distant Metastasis-Free Survival (DMFS)
    DMFS is the length of time from when the participant starts the study until either the cancer spreads from where it started to other parts of the body as assessed by the investigator, or death due to any cause.
  2. Overall-Survival (OS)
    OS is the length of time that people are alive after joining the study.
  3. Number of Participants Who Experience an Adverse Event (AE)
    An AE is a health problem that happens or worsens during a study. Number of participants who experience an AE will be reported.
  4. Number of Participants Who Discontinue Study Treatment Due to an AE
    An AE is a health problem that happens or worsens during a study. Number of participants who discontinue study treatment will be reported.
  5. Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score
    The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" will be scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores will be standardized, so that scores range from 0 to 100. Higher scores indicate a better overall health status. Per protocol, the change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score will be presented.
  6. Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30
    The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning will be scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores will be standardized, so that scores range from 0 to 100. Higher scores indicate a better level of physical functioning. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) combined score will be presented.
  7. Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score on the EORTC QLQ-C30
    The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "Were you limited in doing either your work or other daily activities during the past week?" and " Were you limited in pursuing your hobbies or other leisure time activities during the past week?" will be scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a more impaired level of role functioning. Change from baseline in the role functioning (EORTC QLQ-C30 Items 6-7) combined score will be presented.

Eligibility Criteria

Ages Eligible for Study(Adult, Older Adult)
Sexes Eligible for StudyAll
Accepts Healthy VolunteersNo
Inclusion Criteria
The main inclusion criteria include but are not limited to the following:
Has surgically resected and histologically/pathologically confirmed diagnosis of Stage IIB or IIC, III, or IV cutaneous melanoma
Has not received any prior systemic therapy for their melanoma beyond surgical resection
No more than 13 weeks have passed between final surgical resection that rendered the participant disease-free and the first dose of pembrolizumab
Is disease free at the time of providing documented consent for the study
Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART)
Exclusion Criteria
The main exclusion criteria include but are not limited to the following:
Has ocular or mucosal melanoma
Has cancer that has spread to other parts of the body and cannot be removed with surgery
Has heart failure within the past 6 months
Has received prior cancer therapy or another cancer vaccine
Has another known cancer that that has spread to other parts of the body or has required treatment within the past 3 years
Has severe reaction to study medications or any of their substance used to prepare a drug
Have not recovered from major surgery or have ongoing surgical complications

Contacts and Locations

Sponsors and CollaboratorsMerck Sharp & Dohme LLC
Locations
Highlands Oncology Group ( Site 1943) | Springdale Arkansas, United States, 72762UCLA Hematology/Oncology - Westwood (Building 100) ( Site 1918) | Los Angeles California, United States, 90095UCSF Medical Center at Mission Bay ( Site 1929) | San Francisco California, United States, 94158Yale-New Haven Hospital-Yale Cancer Center ( Site 1933) | New Haven Connecticut, United States, 06510Orlando Health Cancer Institute ( Site 1937) | Orlando Florida, United States, 32806Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center ( Site 1945) | Tampa Florida, United States, 33612Winship Cancer Institute of Emory University ( Site 1940) | Atlanta Georgia, United States, 30322Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 1950) | Marietta Georgia, United States, 30060University of Iowa-Holden Comprehensive Cancer Center ( Site 1935) | Iowa City Iowa, United States, 52242Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Melanoma ( Site 1912) | Baltimore Maryland, United States, 21287Massachusetts General Hospital ( Site 1927) | Boston Massachusetts, United States, 02114Beth Israel Deaconess Medical Center ( Site 1957) | Boston Massachusetts, United States, 02215Dana-Farber Cancer Institute ( Site 1956) | Boston Massachusetts, United States, 02215University of Michigan ( Site 1915) | Ann Arbor Michigan, United States, 48109Cancer and Hematology Centers of Western Michigan ( Site 1932) | Grand Rapids Michigan, United States, 49503John Theurer Cancer Center at Hackensack University Medical Center ( Site 1944) | Hackensack New Jersey, United States, 07601Atlantic Health System ( Site 1925) | Morristown New Jersey, United States, 07960Valley Health Systems - Ridgewood Campus ( Site 1947) | Ridgewood New Jersey, United States, 07450Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 1958) | Mineola New York, United States, 11501NYU Langone Health-Perlmutter Cancer Center ( Site 1917) | New York New York, United States, 10016Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 1908) | New York New York, United States, 10032Memorial Sloan Kettering Cancer Center ( Site 1914) | New York New York, United States, 10065University of North Carolina Medical Center-Lineberger Comprehensive Cancer Center ( Site 1949) | Chapel Hill North Carolina, United States, 27599Duke Cancer Institute ( Site 1911) | Durham North Carolina, United States, 27710Hospital of the University of Pennsylvania Perelman Center for Advanced Medicine ( Site 1905) | Philadelphia Pennsylvania, United States, 19104UPMC Hillman Cancer Center ( Site 1909) | Pittsburgh Pennsylvania, United States, 15232Medical University of South Carolina-Hollings Cancer Center ( Site 1934) | Charleston South Carolina, United States, 29425Sanford Cancer Center ( Site 1951) | Sioux Falls South Dakota, United States, 57104SCRI Oncology Partners ( Site 1910) | Nashville Tennessee, United States, 37203Texas Oncology - Austin ( Site 1903) | Austin Texas, United States, 78731Texas Oncology - Dallas (Sammons) ( Site 1902) | Dallas Texas, United States, 75246University of Texas MD Anderson Cancer Center ( Site 1920) | Houston Texas, United States, 77030Inova Schar Cancer Institute ( Site 1900) | Fairfax Virginia, United States, 22031Fred Hutchinson Cancer Center ( Site 1901) | Seattle Washington, United States, 98109Clinica Adventista Belgrano-Oncology ( Site 2204) | Caba. Buenos Aires, Argentina, C1430EGFHospital Italiano de Buenos Aires-Clinical Oncology ( Site 2202) | Ciudad Autonoma de Buenos Aires Buenos Aires, Argentina, C1199ABBInstituto Alexander Fleming-Alexander Fleming ( Site 2203) | Buenos Aires Buenos Aires F.D., Argentina, 1426ANZCentro Privado de RMI Río Cuarto S.A. II ( Site 2201) | Río Cuarto Córdoba Province, Argentina, X5800ALBHospital Aleman ( Site 2200) | Buenos Aires , Argentina, C1118AATSanatorio Finochietto ( Site 2205) | Buenos Aires , Argentina, C1187AANWestmead Hospital ( Site 1001) | Westmead New South Wales, Australia, 2145Melanoma Institute Australia-Clinical Trials Unit ( Site 1000) | Wollstonecraft New South Wales, Australia, 2065Princess Alexandra Hospital ( Site 1003) | Brisbane Queensland, Australia, 4102Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 1005) | Melbourne Victoria, Australia, 3000Paula Fox Melanoma & Cancer Centre ( Site 1004) | Melbourne Victoria, Australia, 3004One Clinical Research ( Site 1002) | Nedlands Western Australia, Australia, 6009UZ Brussel-Medische oncologie ( Site 3405) | Brussels Bruxelles-Capitale, Region de, Belgium, 1090Ziekenhuis Oost-Limburg, Campus St.-Jan ( Site 3402) | Genk Limburg, Belgium, 3600UZ Gent ( Site 3403) | Ghent Oost-Vlaanderen, Belgium, 9000UZ Leuven ( Site 3400) | Leuven Vlaams-Brabant, Belgium, 3000AZ Groeninge Campus Kennedylaan-Oncology ( Site 3401) | Kortrijk West-Vlaanderen, Belgium, 8500Centro Avançado de Tratamento Oncológico- CENANTRON ( Site 2303) | Belo Horizonte Minas Gerais, Brazil, 30130-090ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 2302) | Ijuí Rio Grande do Sul, Brazil, 98700-000Hospital Nossa Senhora da Conceição ( Site 2309) | Porto Alegre Rio Grande do Sul, Brazil, 91350-200Instituto Nacional de Câncer - INCA-Pesquisa Clinica HC II ( Site 2305) | Rio de Janeiro , Brazil, 20220-410ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 2300) | São Paulo , Brazil, 01246-000Cross Cancer Institute ( Site 1104) | Edmonton Alberta, Canada, T6G 1Z2BC Cancer Vancouver-Clinical Trials Unit ( Site 1106) | Vancouver British Columbia, Canada, V5Z 4E6William Osler Health System ( Site 1105) | Brampton Ontario, Canada, L6R 3J7Sunnybrook Research Institute ( Site 1103) | Toronto Ontario, Canada, M4N 3M5Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 1102) | Toronto Ontario, Canada, M5G 2M9Centre Hospitalier de l'Université de Montréal-Unité de Recherche Clinique en Oncologie et Hématolo ( Site 1100) | Montreal Quebec, Canada, H2X 0X9Centre intégré de cancérologie du CHU de Québec Université L-Hemato-Oncology ( Site 1101) | Québec Quebec, Canada, G1J 1Z4FALP-UIDO ( Site 2400) | Santiago Region M. de Santiago, Chile, 7500921Clínica UC San Carlos de Apoquindo-Hemato-Oncology ( Site 2402) | Santiago Region M. de Santiago, Chile, 7620002Bradfordhill ( Site 2401) | Santiago Region M. de Santiago, Chile, 8420383Clinica Somer-Unidad de Investigacion y Docencia ( Site 2506) | Rionegro Antioquia, Colombia, 054040Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 2500) | Bogotá Bogota D.C., Colombia, 111321IMAT S.A.S ( Site 2503) | Montería Departamento de Córdoba, Colombia, 230002Fundación Valle del Lili ( Site 2505) | Cali Valle del Cauca Department, Colombia, 760032Herlev and Gentofte Hospital ( Site 3301) | Copenhagen Capital Region, Denmark, 2730Aalborg Universitetshospital, Syd ( Site 3302) | Aalborg North Denmark, Denmark, 9000Odense Universitetshospital ( Site 3300) | Odense C Region Syddanmark, Denmark, 5000Centre Hospitalier Universitaire de Nice - Hôpital l'Archet-Dermatology Department ( Site 1211) | Nice Alpes-Maritimes, France, 06200Assistance Publique Hôpitaux de Marseille - Hôpital de la Ti-Service de Dermatologie et Cancérologi ( Site 1203) | Marseille Bouches-du-Rhone, France, 13385Centre Georges François Leclerc ( Site 1210) | Dijon Cote-d Or, France, 21079CHU Besançon ( Site 1209) | Besançon Doubs, France, 25030CHU de Bordeaux Hop St ANDRE-Service de Dermatologie ( Site 1204) | Bordeaux Gironde, France, 33075Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 1206) | Rennes Ille-et-Vilaine, France, 35042Hopital Claude Huriez - CHU de Lille ( Site 1207) | Lille Nord, France, 59037centre hospitalier lyon sud-Service de dermatologie ( Site 1202) | Pierre-Bénite Rhone, France, 69310CHU d'Amiens-Picardie - Hôpital Sud-Dermatologie ( Site 1208) | Amiens Somme, France, 80054Gustave Roussy-Dermatologie ( Site 1201) | Villejuif Val-de-Marne, France, 94800Hôpital Saint-Louis ( Site 1200) | Paris , France, 75010Universitätsmedizin Mannheim ( Site 1305) | Mannheim Baden-Wurttemberg, Germany, 68167Universitaetsklinikum Augsburg ( Site 1312) | Augsburg Bavaria, Germany, 86156Klinik und Poliklinik für Dermatologie und Allergologie-Dermato-oncology ( Site 1315) | München Bavaria, Germany, 80337Universitätsmedizin Göttingen - Georg-August-Universität-Dermatology ( Site 1308) | Göttingen Lower Saxony, Germany, 37075Universitätsmedizin Rostock-Klinik und Poliklinik für Dermatologie und Venerologie ( Site 1310) | Rostock Mecklenburg-Vorpommern, Germany, 18057Universitaetsklinikum Koeln ( Site 1307) | Cologne North Rhine-Westphalia, Germany, 50937Universitaetsklinikum Essen-Klinik für Dermatologie, Venerologie und Allergologie ( Site 1300) | Essen North Rhine-Westphalia, Germany, 45147Johannes Wesling Klinikum Minden-Skin Cancer Center Minden ( Site 1301) | Minden North Rhine-Westphalia, Germany, 32429Universitaetsklinikum des Saarlandes ( Site 1313) | Homburg Saarland, Germany, 66424SRH Wald-Klinikum Gera-Zentrum für klinische Studien ( Site 1306) | Gera Thuringia, Germany, 07548Charité Universitaetsmedizin Berlin - Campus Mitte-Hauttumorcentrum Charité (HTCC) ( Site 1302) | Berlin , Germany, 10115Universitaetsklinikum Hamburg-Eppendorf ( Site 1309) | Hamburg , Germany, 20246General Hospital of Athens "Laiko"-First Department of Internal Medicine ( Site 3700) | Athens Attica, Greece, 115 26Metropolitan Hospital-A' Oncology Dpt ( Site 3701) | Neo Faliro Attica, Greece, 185 47Bioclinic Thessalonikis Private Clinic Single Member S.A.-Oncology ( Site 3703) | Thessaloniki Central Macedonia, Greece, 546 22European Interbalkan Medical Center-Oncology Department ( Site 3702) | Thessaloniki , Greece, 570 01Emek Medical Center ( Site 2003) | Afula , Israel, 1834111Hadassah Medical Center ( Site 2004) | Jerusalem , Israel, 9112001Rabin Medical Center ( Site 2000) | Petah Tikva , Israel, 4941492Sheba Medical Center ( Site 2001) | Ramat Gan , Israel, 5265601Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1401) | Milan Lombardy, Italy, 20133Istituto Europeo di Oncologia IRCCS ( Site 1404) | Milan Lombardy, Italy, 20141Azienda Ospedaliero Universitaria Senese-U.O.C. Immunoterapia Oncologica ( Site 1402) | Siena Tuscany, Italy, 53100AO Santa Maria della Misericordia ( Site 1403) | Perugia Umbria, Italy, 06129Istituto Nazionale Tumori IRCCS Fondazione Pascale-s.c. melanoma, immunoterapia oncologica e terapi ( Site 1400) | Naples , Italy, 80131Nagoya University Hospital ( Site 4201) | Nagoya Aichi-ken, Japan, 466-8560Shizuoka Cancer Center ( Site 4202) | Nagaizumi-cho,Sunto-gun Shizuoka, Japan, 411-8777National Cancer Center Hospital ( Site 4200) | Chūō Tokyo, Japan, 104-0045Capital, Coast and Hutt Valley District - Wellington Regional Hospital ( Site 1502) | Newtown Wellington Region, New Zealand, 6021Harbour Cancer & Wellness ( Site 1500) | Auckland , New Zealand, 1023Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 2909) | Poznan Greater Poland Voivodeship, Poland, 60-569Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2908) | Bydgoszcz Kuyavian-Pomeranian Voivodeship, Poland, 85-796Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2903) | Siedlce Masovian Voivodeship, Poland, 08-110Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 2900) | Warsaw Masovian Voivodeship, Poland, 02-781Bialostockie Centrum Onkologii ( Site 2905) | Bialystok Podlaskie Voivodeship, Poland, 15-027Uniwersyteckie Centrum Kliniczne-Klinika Chirurgii Onkologicznej, Transplantacyjnej i Ogólnej ( Site 2906) | Gdansk Pomeranian Voivodeship, Poland, 80-214Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2907) | Gliwice Silesian Voivodeship, Poland, 44-101Zachodniopomorskie Centrum Onkologii ( Site 2904) | Szczecin West Pomeranian Voivodeship, Poland, 71-730Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Onkologii Klinicznej, Dzial Ch ( Site 2902) | Kielce Świętokrzyskie Voivodeship, Poland, 25-734Instituto Português de Oncologia de Lisboa Francisco Gentil ( Site 3601) | Lisbon Lisbon District, Portugal, 1099-023Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 3602) | Lisbon , Portugal, 1449-005Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 3603) | Lisbon , Portugal, 1649-035Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 3604) | Porto , Portugal, 4200-072Medical Oncology Centre of Rosebank ( Site 4106) | Johannesburg Gauteng, South Africa, 2196Wilgers Oncology Centre ( Site 4103) | Pretoria Gauteng, South Africa, 0040Cape Town Oncology Trials ( Site 4100) | Cape Town Western Cape, South Africa, 7570Kyungpook National University Chilgok Hospital-Hematology/oncology ( Site 3904) | Daegu Taegu-Kwangyokshi, South Korea, 41404Chungnam national university hospital-Department of Internal Medicine ( Site 3903) | Daejeon Taejon-Kwangyokshi, South Korea, 35015Seoul National University Hospital-Oncology ( Site 3902) | Seoul , South Korea, 03080Severance Hospital, Yonsei University Health System-Medical oncology ( Site 3901) | Seoul , South Korea, 03722Samsung Medical Center-Division of Hematology/Oncology ( Site 3900) | Seoul , South Korea, 06351HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Site 1600) | Barcelona Catalonia, Spain, 08036HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 1603) | Pozuelo de Alarcón Madrid, Spain, 28223Hospital Universitario Ramón y Cajal ( Site 1602) | Madrid Madrid, Comunidad de, Spain, 28034H.R.U Málaga - Hospital General-Oncology ( Site 1605) | Málaga Malaga, Spain, 29011HOSPITAL CLINICO DE VALENCIA ( Site 1604) | Valencia Valenciana, Comunitat, Spain, 46010Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1601) | Barcelona , Spain, 08035Skånes Universitetssjukhus Lund ( Site 3201) | Lund Skåne County, Sweden, 22185Sahlgrenska Universitetssjukhuset ( Site 3200) | Gothenburg Västra Götaland County, Sweden, 413 45UniversitätsSpital Zürich-Dermatology ( Site 1700) | Zürich Flughafen Canton of Zurich, Switzerland, 8058Kantonsspital Graubünden-Medizin ( Site 1703) | Chur Kanton Graubünden, Switzerland, 7000Chang Gung Memorial Hospital at Kaohsiung ( Site 4000) | Kaohsiung City , Taiwan, 83301National Cheng Kung University Hospital-Clinical Trial Center ( Site 4004) | Tainan , Taiwan, 704National Taiwan University Hospital ( Site 4001) | Taipei , Taiwan, 10002Chang Gung Medical Foundation-Linkou Branch ( Site 4003) | Taoyuan , Taiwan, 33305Hacettepe Universite Hastaneleri ( Site 3006) | Ankara , Turkey (Türkiye), 06230Memorial Ankara Hastanesi-Medical Oncology ( Site 3010) | Ankara , Turkey (Türkiye), 06520Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 3002) | Ankara , Turkey (Türkiye), 06800Acibadem Universitesi Atakent Hastanesi-Medical Oncology ( Site 3008) | Istanbul , Turkey (Türkiye), 34303TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 3003) | Istanbul , Turkey (Türkiye), 34722Ege University Medical Faculty Hospital ( Site 3011) | Izmir , Turkey (Türkiye), 35100I.E.U. Medical Point Hastanesi-Oncology ( Site 3005) | Izmir , Turkey (Türkiye), 35575Bristol Haematology and Oncology Centre ( Site 1811) | Bristol Bristol, City of, United Kingdom, BS2 8EDAddenbrooke's Hospital ( Site 1800) | Cambridge Cambridgeshire, United Kingdom, CB2 2QQNorfolk and Norwich University Hospitals NHS Foundation Trust ( Site 1813) | Cringleford England, United Kingdom, NR4 7UYUniversity College London Hospital ( Site 1807) | London London, City of, United Kingdom, NW1 2PGROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 1804) | London London, City of, United Kingdom, SW3 6JJWestern General Hospital ( Site 1806) | Edinburgh Midlothian, United Kingdom, EH4 2XUThe Churchill Hospital ( Site 1805) | Oxford Oxfordshire, United Kingdom, OX3 7LESt James's University Hospital-Leeds Cancer Centre ( Site 1808) | Leeds , United Kingdom, LS9 7TFThe Christie NHS Foundation Trust ( Site 1814) | Manchester , United Kingdom, m20 4bx
Investigators
Study Director: Medical Director, Merck Sharp & Dohme LLC